First Report on Remdesivir Use for the Treatment of Respiratory Syncytial Virus in Five Allogeneic Hematopoietic Cell Transplant Recipients

The Journal of Infectious Diseases 2026 Open access

Read full text
Authors: Denise J. McCulloch, Fareed Khawaja, Frank P. Tverdek, Emily S. Ford, Surabhi B Vora, Alpana Waghmare, Nancy Vuong, Roy F Chemaly, J Andrew Hill
DOI: 10.1093/infdis/jiag213
Cited by: 1
References: 12

Abstract

Respiratory syncytial virus (RSV) infection causes substantial morbidity among hematopoietic cell transplant (HCT) patients and lacks approved therapies. Remdesivir demonstrates antiviral activity in vitro, but data in humans are lacking. We describe 5 HCT recipients with RSV lower respiratory tract infection who were treated with remdesivir with clinical improvement.

Fields of Study & Subjects

Respiratory viral infections research Animal Virus Infections Studies Virus-based gene therapy research

Publication details

Journal / source
The Journal of Infectious Diseases
Publisher
Oxford University Press (OUP)
Volume
234
Issue
3
Pages
e552-e555
Publication date
8 April 2026
Language
EN